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Pancreatic α-amylase inhibitors oﬀer an eﬀective strategy to lower the levels of post prandial hyperglycemia via control of starch
breakdown. Eleven Ayurvedic Indian medicinal plants with known hypoglycemic properties were subjected to sequential solvent
extraction and tested for α-amylase inhibition, in order to assess and evaluate their inhibitory potential on pancreatic α-amylase.
Analysis of 91 extracts, showed that 10 exhibited strong Human Pancreatic Amylase (HPA) inhibitory potential. Of these, 6
extracts showed concentration dependent inhibition with IC50 values, namely, cold and hot water extracts from Ficus bengalensis
bark (4.4 and 125μgmL
−1), Syzygium cumini seeds (42.1 and 4.1μgmL
−1), isopropanol extracts of Cinnamomum verum leaves
(1.0μgmL
−1)a n dCurcuma longa rhizome (0.16μgmL
−1). The other 4 extracts exhibited concentration independent inhibition,
namely, methanol extract of Bixa orellana leaves (49μgmL
−1), isopropanol extract from Murraya koenigii leaves (127μgmL
−1),
acetone extracts from C. longa rhizome (7.4μgmL
−1)a n dTribulus terrestris seeds (511μgmL
−1). Thus, the probable mechanism
of action of the above fractions is due to their inhibitory action on HPA, thereby reducing the rate of starch hydrolysis leading to
lowered glucose levels. Phytochemical analysis revealed the presence of alkaloids, proteins, tannins, cardiac glycosides, ﬂavonoids,
saponins and steroids as probable inhibitory compounds.
1.Introduction
Diabetes mellitus is a carbohydrate metabolism disorder of
endocrine system due to an absolute or relative deﬁciency
of insulin secretion, action, or both [1]. The disorder aﬀects
more than 100 million people worldwide and by 2030 it is
predictedtoreach366million.Themostprevalentformboth
intheglobalandIndianscenarioisthenoninsulindependent
diabetes mellitus (NIDDM type 2) which is associated with
elevated postprandial hyperglycemia [2].
Pancreatic α-amylase (E.C. 3.2.1.1), is a key enzyme in
thedigestivesystemandcatalysestheinitialstepinhydrolysis
of starch to maltose and ﬁnally to glucose. Degradation of
this dietary starch proceeds rapidly and leads to elevated
post prandial hyperglycemia (PPHG). It has been shown
that activity of Human Pancreatic α-amylase (HPA) in the
small intestine correlates to an increase in post-prandial
glucose levels, the control of which is therefore an important
aspect in treatment of diabetes [3]. Hence retardation
of starch digestion by inhibition of enzymes such as α-
amylase would play a key role in the control of diabetes.
However, the discovery of speciﬁc high-aﬃnity inhibitors of
pancreatic α-amylase for the development of therapeutics
has remained elusive. Inhibitors currently in clinical, use for
example, acarbose, miglitol, and voglibose, are known to
inhibit a wide range of glycosidases such as α-glucosidase
and α-amylase. Because of their nonspeciﬁcity in targeting
diﬀerent glycosidases, these hypoglycemic agents have their
limitations and are known to produce serious side eﬀects.
Therefore, the search for more safer, speciﬁc, and eﬀective
hypoglycemic agents has continued to be an important area
of investigation with natural extracts from readily available
traditional medicinal plants oﬀering great potential for
discovery of new antidiabetic drugs [4, 5].
While plant derivatives with purported hypoglycemic
properties have been used in folk medicine and traditional2 Evidence-Based Complementary and Alternative Medicine
healing systems, very few of these traditional anti-diabetic
plants have received proper scientiﬁc or medical scrutiny
despite recommendations by World Health Organization
(WHO). Ayurveda and other Indian traditional approaches
have described more than 800 plants in the Indian subconti-
nent, known to possess antidiabetic potential. These require
to be eﬀectively studied and in fact only few of them have
beencharacterizedfortheirmechanisticactions[6–9].Plants
such as Barringtonia racemosa, Phyllanthus amarus, and so
forth, have been tested for the presence of pancreatic α-
amylase inhibitors from various regions of the world [10–
15]. Most of them have been tested on porcine pancreatic α-
amylase (PPA) and salivary amylase while reports on their
eﬀect on human pancreatic amylase (HPA), if any, are scarce.
In this study, we have selected medicinal plants from
the Indian Ayurvedic system with known hypoglycemic
or antidiabetic activity, in an attempt to screen for new
inhibitors for HPA. The selections of these plants were based
on their traditional usage and also taking into consideration
previous studies that have demonstrated their antidiabetic
properties (Table 1), thus providing a preliminary screening
assessment [16–26]. However, no known reports of these
plants as HPA inhibitors exist. Sequential solvent extracts
of Azadirachta indica A. Juss., Bixa orellana L., Bougainvillea
spectabilis Willd., Cinnamomum verum J. S. Presl, Curcuma
longa L., Ficus bengalensis L., Ficus racemosa L., Momordica
charantia L., Murraya koenigii L. Spreng., Syzygium cumini
L. Skeels,a n dTribulus terrestris L. were tested for the
presence of PPA and HPA inhibitors. The lead extracts
have also been subjected to preliminary kinetics on HPA to
ascertain the type of inhibition as well as for phytochemical
analysis to determine the probable inhibitory compounds
present.
2. Methods
2.1. Chemicals. Starch, porcine pancreatic α-amylase (PPA),
methanol, isopropanol, acetone, methyl-butyl-tertiary ether,
cyclohexane, and dimethylsulfoxide (DMSO) were pur-
chased from SRL Pvt. Ltd, Mumbai, India. 3,5-dinitro-
salicylicacid (DNSA) was obtained from HiMedia Labora-
tories, Mumbai, India. Human pancreatic α-amylase (HPA)
and acarbose were purchased from Sigma Aldrich, USA. All
other chemicals procured were from local manufacturer and
were of AR grade.
2.2. Plant Material. In this study, anti-diabetic plants from
theIndiansub-continentwereselectedonthebasisofknown
ethno botanical/traditional Ayurvedic literature. Plants were
obtained from Pune city and nearby areas of the Western
Ghats, India, in the months of August–January. The plants,
their voucher numbers (V. No.), the part(s) used, and the
hypoglycemic properties as seen from literature search are
listed in Table 1. A specimen of each plant was submitted
to Botanical Survey of India (BSI), Pune, India, for authen-
tication. The plants were separated into their various parts,
namely., roots, stem, leaves, seeds and so forth, washed with
tap water, air-dried in shade, and processed immediately as
mentioned below.
2.3. Preparation of Plant Extracts. The air-dried plant mate-
rial (60–100g) was crushed with liquid nitrogen, powdered,
and successively extracted in polar to nonpolar solvent on
an increasing degree of non-polarity [27]. The diﬀerent
extracts obtained sequentially were with cold water, hot
water,methanol,isopropanol,acetone,methyl-butyl-tertiary
ether, and cyclohexane. This kind of sequential extraction
was performed taking into consideration the fact that
traditional methods of preparing herbal formulations are
mainly aqueous. Also, aqueous extracts contain peptides,
proteins, or glycans, which would otherwise be denatured by
organic solvents and high-temperature extraction. Distilled
water was added to the crushed material in a ratio of 1:4
(w/v) and kept at 30
◦C( 2 4h )a n d5 5
◦C (2h) at 130rpm for
cold-and hot-water extracts, respectively. For each solvent,
theextractwasﬁltered,centrifuged,andtheresiduecollected
for subsequent solvent extraction. The organic solvents were
added in a ratio of 1:3 (w/v) and reﬂuxed with the residue
for 3h at their respective boiling temperatures. Each extract
w a sﬁ l t e r e da n ds t o r e da t−20
◦C.
2.4. α-Amylase Inhibition and Kinetic Studies. PPA was used
for preliminary screening of α-amylase inhibitors from the
extracts. The inhibition assay was performed using the
chromogenic DNSA method [28]. The total assay mixture
composed of 500μL of 0.02M sodium phosphate buﬀer
(pH 6.9 containing 6mM sodium chloride), 0.04 units
of PPA solution, and extracts at concentration from 0.1–
1.5mgmL−1(w/v) were incubated at 37
◦C for 10min. After
pre-incubation, 500μL of 1% (v/v) starch solution in the
above buﬀer was added to each tube and incubated at 37
◦C
for 15min. The reaction was terminated with 1.0mL DNSA
reagent, placed in boiling water bath for 5min, cooled to
room temperature, diluted, and the absorbance measured
at 540nm. The control reaction representing 100% enzyme
activity did not contain any plant extract. To eliminate the
absorbance produced by plant extract, appropriate extract
controls were also included. One unit of enzyme activity is
deﬁned as the amount of enzyme required to release one
micromole of maltose from starch per min under the assay
conditions.
For the determination of the inhibitor concentration at
which 50% inhibition of enzyme activity occurs (IC50), the
assay was performed as above except that the inhibitor/plant
extract concentrations were varied from 0.1–150μg. Acar-
bose was used as a positive control at a concentration range
of 6.5μg–32.8μg. The IC50 values were determined from
plots of percent inhibition versus log inhibitor concentration
and calculated by logarithmic regression analysis from the
mean inhibitory values. The IC50 values were deﬁned as
the concentration of the extract, containing the α-amylase
inhibitor that inhibited 50% of the PPA or HPA activity.
Other quantiﬁers were deﬁned as follows:
% R e l a t i v ee n z y m ea c t i v i t y= (enzyme activity of
test/enzyme activity of control) ∗ 100;
%inhibition in the α-amylase activity = (100 −%r e l a t i v e
enzyme activity).
For kinetic experiments involving concentration inde-
pendent inhibition, the inhibitor/extracts were taken at theirEvidence-Based Complementary and Alternative Medicine 3
Table 1: Plant sources and their traditional uses.
Plants namea V. nob Family Parts used Hypoglycemic and medicinal properties Ref.
Azadirachta indica
A. Juss. (Neem)
GMAI3 Meliaceae Leaves
Antihyperglycemic activity, increase in glucose
uptake and glycogen deposition, inhibits activity
of epinephrine on glucose metabolism resulting
in utilization of peripheral glucose. Does not alter
cortisol concentration.
[17, 18]
Bixa orellana L.
(Sindhuri)
BOSP1 Bixaceae Leaves Hypoglycemic activity by lowering blood glucose
by stimulating peripheral utilization of glucose.
[19]
Bougainvillea
spectabilis Willd.
(Bougainvilla)
MARCKBS2 Nyctaginaceae Leaves Hypoglycemic eﬀect is by D-pinitol which exerts
insulin-like eﬀect and inhibits α-glucosidase.
[20]
Cinnamomum
verum J.S.Presl
(Cinnamon)
CIZYS1 Lauraceae Leaves
Hypoglycemic activity is by enhancing insulin
activity, increasing lipid metabolism and
antioxidant status, capillary function.
[21]
Curcuma longa L.
(Turmeric)
SUCL1 Zingiberaceae Rhizome
Hypoglycemic, hypolipidemic, and antioxidant
property. Decreased inﬂux of glucose in polyol
pathway, increasing NADPH/NADP ratio and
increased activity of glucose peroxidase.
[22]
Ficus bengalensis L.
(Banyan)
GMFB1 Moraceae Leaves,
Bark
Stimulates insulin secretion from beta cells
inhibits insulin degradative process.
[23]
Ficus recemosa L.
(Umbar)
GMFR2 Moraceae Fruit pulp Hypoglycemic activity by β-sitosterol isolated was
found to lower the blood glucose level.
[24]
Momordica
charantia L.
(Karela,)
(Bitter gourd)
MARCK1 Cucurbitaceae Leaves,
fruit, seeds
Hypoglycemic eﬀect by inhibition of
glucose-6-phosphatase and
fructose-1-6-biphosphatase in liver and
stimulation of hepatic glucose-6-phosphate
dehydrogenase.
[25]
Murraya koenigii L.
Spreng
(Curry Leaves)
SP-2 Rutaceae Leaves Increases glucogenesis and decreases
glycogenolysis and gluconeogenesis.
[26]
Syzygium cumini L.
Skeels (Jamun)
SPSC2 Myrtaceae Seeds
Reduces blood glucose level, increase in serum
insulin level, exhibits insulinase activity.
Hypoglycemic activity mediated through insulin
release mechanism, glycogen content and hepatic
glucokinase, hexokinase, glucose-6-phosphate,
and phosphofructokinase levels in diabetic mice.
[4, 17]
Tribulus terrestris
L. (Gokshura)
SUTT1 Zygophyllaceae Seeds Hypoglycemic activity by inhibiting oxidative
stress.
[16]
aThe common Indian name for the plant is given in brackets.
bVoucher numbers as given by Botanical Survey of India, Pune.
IC50 values and incubated with HPA while the substrate
(starch) concentration was varied from 0.5–5mgmL−1 and
reaction allowed to proceed as mentioned above. Kinetic
a n a l y s i sw a sp e r f o r m e db a s e do nL i n e w e a v e r - B u r kd o u b l e
reciprocal plots and the kinetic parameters calculated using
Origin 6.0 software from Originlab, USA.
2.5. Preliminary Phytochemical Analysis. Qualitative phyto-
chemical analyses of the extracts were performed according
to Parekh and Chanda [29]. Alkaloids were detected by
Mayer’s reagent, while for cardiac glycosides the Keller-
Kiliani test was carried out. Steroids were detected using
the Liebermann-Burchard test. Bradford reagent was used
to detect the proteins while the frothing test was used for
detection of saponins.
2.6. GCMS Analyses. Analyses of the organic extracts
exhibiting ≥50% inhibition on the PPA or HPA activ-
ity were performed on a GCMS-MS (Varian 4000) gas
chromatograph equipped with DB 5ms capillary column4 Evidence-Based Complementary and Alternative Medicine
(30m × 0.25mm ID). Helium was the carrier gas with
ﬂow rate of 1mL/min, the injector mode—split (1:60),
the injection volume 1μL, the temperature program used
is as follows: 50
◦C (3min), then increased to 280
◦Ca t
15
◦C /min, held at 280
◦C( 1 0 m i n )a n dt e m p e r a t u r es c a n ,
m/z 35–800. Appropriate solvent controls were also run.
The identiﬁcation of the components was based on the
comparison of their mass spectra with those of NIST-Wiley
2008 library.
2.7. Statistical Analysis. All experiments were performed
in 3 diﬀerent sets, with each set in triplicates. The data
are expressed as mean ± SEM. Statistical analysis was
performed for analysis of variance (ANOVA) followed by F-
test using SPSS 11.5. Those P-values ≤ .05 were considered
as signiﬁcant.
3. Results
3.1. Screening of Plant Extracts on α-Amylase Inhibition. The
plants from the Indian sub-continent exhibiting potential
hypoglycemic properties were sequentially extracted with
polar to non-polar solvents and a total of 91 extracts
obtained. It should be noted that while generally cold-
and hot-water extracts are most commonly used in the
traditional method of preparing medicines in Ayurveda,
chances of missing out on bioactive principles with better
amylase inhibitory potential from less-polar solvents are
high. Hence the rationale for performing extractions from
polar to non-polar solvents is not only to conﬁrm and
validatetheinhibitoryactivity,iffound,inanyoftheaqueous
extractions performed in the traditional manner but also
to search for newer and higher speciﬁc aﬃnity inhibitors
in less-polar solvents. PPA was used as a target enzyme for
screening of inhibitory activity from the above mentioned
ninety-one plant extracts. The control reaction representing
100%enzymeactivitywas0.21U/mLforPPAand0.25U/mL
for HPA. Extract samples dissolved in DMSO contained as
a ﬁnal yield of 1.5mgmL−1 of the dried extract and the
enzyme activity of both PPA and HPA was not aﬀected
by DMSO at the concentration used. Appropriately diluted
plant extract was used for enzyme inhibition assay and
the activity obtained with each extract was normalized to
percent relative activity (Figure 1) from which the percent
inhibition was calculated. Less than 50% PPA inhibition
was observed for extracts of A. indica (leaves), B. spectabilis
(leaves), F. bengalensis (leaves), F. racemosa (fruit), M.
charantia (leaves, fruit, and seeds) as well as for extracts of
MTBE and cyclohexane. Some of the extracts were found to
marginally activate PPA. Of the rest, 12 extracts exhibited
signiﬁcant inhibition (≥50%) on PPA enzyme activity.
The most signiﬁcant inhibitory activity was obtained with
t h ea q u e o u se x t r a c t so fF. bengalensis bark (0.38mgmL−1
and 0.14mgmL−1 for cold and hot water, resp.), S.
cumini (0.38mg mL−1 and 0.13mgmL−1 for cold and hot
water), methanol extracts of B. orellana (0.04mgmL−1),
C.longa (1.5mgmL−1), C. verum (2.23mgmL−1), iso-
propanol extracts of C. longa (0.01mgmL−1), C. verum
(0.06mgmL−1), M. koenigi (0.05mgmL−1)a n da c e t o n e
extracts of C. longa (0.02mgmL−1)a n dT. terrestris
(0.33mgmL−1). On checking the stability of these extracts
over a period of time, all the extracts except for C. verum
methanol extract were stable even after a period of two
months. Thus, further experiments were carried out with
11 stable extracts (excluding C. verum methanol extract)
exhibiting PPA inhibition ≥50%. These extracts exhibited
signiﬁcant inhibition (P ≤ .05) with IC50 values ranging
between 10 and 920μgmL
−1. C. longa and M. koenigii
isopropanol extracts and S. cumini cold water extract showed
the best IC50 value of 10μgmL−1 against PPA. The known
PPA inhibitor, acarbose, taken as a positive control exhibited
an IC50 value of 10.2μgmL−1. Those extracts exhibiting
≥50%inhibitionforPPAweretakenasleadextractsandwere
further tested for inhibition studies against HPA.
3.2. Extracts Exhibiting ≥50% Inhibition on Human Pancre-
aticAmylase(HPA)Activity. Ofthe11leadextractsobtained,
C. longa methanol extract was not tested against HPA since
the concentration required for inhibiting PPA (920μgmL−1)
was high. For the other 10 extracts, diﬀering IC50 values
were obtained for HPA as compared to PPA, with values
ranging from 0.16μgmL−1 to 511μgmL−1 (Figure 2). Of
these, B. orellana methanol extract and F. bengalensis hot-
water extract showed similar IC50 values for HPA as seen
for PPA, while M. koenigii isopropanol, S. cumini cold-
water, and T. terrestris a c e t o n ee x t r a c t sr e q u i r e dh i g h e r
concentrations for 50% HPA inhibition as compared to PPA.
However, ﬁve extracts, namely, isopropanol extracts of C.
longa l (0.16μgmL−1)a n dC. verum (1.0μgmL−1), cold-
water extract of F. bengalensis (4.4μgmL−1), and hot-water
extracts of S. cumini (4.1μgmL−1) could inhibit HPA at
much lower concentrations than PPA. Acarbose inhibited
H P Aw i t ha nI C 50 value of 10.5μgmL−1. Thus, these crude
extracts could inhibit HPA at much lower concentrations
than even acarbose and would therefore be good candidates
to test for high-aﬃnity inhibitors. For this, inhibitor kinetic
studies were performed to determine the type of inhibition.
3.3. Kinetic Studies. The inhibitory assays were performed
using extracts at diﬀerent dilutions in order to check for
concentration dependent or independent inhibition. Of
the 10 plant extracts studied, 6 extracts, namely, C. longa
(isopropanol), C. verum (isopropanol), F. bengalensis (cold
and hot water), and S. cumini (cold and hot water) exhibited
concentration dependent (competitive) inhibition. Plots of
percent inhibition versus log concentration (Figure 3)o f
extracts showed typical sigmoidal dose response curves with
50% inhibition at concentrations 0.16μgmL−1,1 . 0μgmL−1,
4.4μgmL−1, 125μgmL−1, 42.1μgmL−1,a n d4 . 1 μgmL−1,
respectively, for HPA. The lowest IC50 value for HPA was
noted for C. longa isopropanol extract at 0.16μgmL−1.M a n y
of these extracts were found to competitively inhibit HPA
at much lower concentrations than the commercially used
inhibitor acarbose (10.5μgmL−1).
On the other hand, 4 extracts, namely, B. orellana
(methanol), C. longa (acetone), M. koenigii, (isopropanol),
and T. terrestris L. (acetone) extracts exhibited concentrationEvidence-Based Complementary and Alternative Medicine 5
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Figure 1: The percent relative enzyme activity (RA %) of porcine pancreatic α-amylase (PPA) on inhibition with diﬀerent extracts. (a)
Cold-water extracts (CWE). (b) Hot-water extracts (HWE). (c) Methanol extracts (ME). (d) Isopropanol extracts (IP). (e) Acetone extracts
(AE) of the listed plants. Pure porcine pancreatic α-amylase serves as control. The data is indicated as the mean ± SEM; (n = 3). The students
F-test was used and the bars with diﬀerent asterisks (∗∗∗, ∗∗, ∗) show signiﬁcant diﬀerence with respect to control (P < .05).
independent inhibition for HPA. A preliminary study for the
probablemodeofinhibitionwasperformedusingMichaelis-
Menten kinetics at their IC50value with varying substrate
concentrations. The double reciprocal Lineweaver-Burk plot
showed a decrease in both Vmax and Km values for all
the 4 extracts studied, thereby suggesting an uncompetitive
type of inhibition (Figure 4). For control HPA, that is,
without inhibitor, using starch as the substrate, the apparent
Vmax and Km values of 0.17μMmin−1, 2.12mg, respec-
tively, were obtained. These kinetic parameters decreased to
0.08μMmin−1 and 1.36mg for B. orellana,0 . 1 0 μMmin−1
and 1.61mg for C. longa,0 . 0 7 μMmin−1 and 1.02mg for6 Evidence-Based Complementary and Alternative Medicine
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Figure 2: IC50 values of the extracts exhibiting ≥50% inhibition
on Porcine pancreatic α-amylase and Human pancreatic α-amylase
enzyme activity. The data is calculated as the mean ± SEM; (n
= 3). The students F-test was used and the bars with diﬀerent
asterisks (∗∗∗, ∗∗, ∗) show signiﬁcant diﬀerence with respect to
control (P < .05). Acarbose is taken as the standard α-amylase
inhibitor.
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M. koenigii, and 0.14μMmin−1 and 1.71mg for T. terrestris,
respectively.
3.4. Phytochemical and GC-MS Analysis. Preliminary qual-
itative phytochemical analysis was performed to determine
the probable type of compounds present in the extracts
causing HPA inhibition. The results showed the presence
of diﬀerent types of active constituents such as proteins,
cardiac glycosides, saponins, alkaloids, ﬂavonoids, and so
forth. (Table 2).
Using the Wiley-NIST library, GC-MS identiﬁcation of
the compounds based on the retention time, peak area,
molecular mass, and molecular formula are shown in
Table 3.
4. Discussion
The aim of the present study was to investigate the HPA
inhibitory activity from medicinal plants known in the
Indian Ayurvedic system for their anti-diabetic properties.
To date no reports of compounds responsible for HPA inhi-
bition from these plants exist in the literature and we report
here for the ﬁrst time their inhibitory on HPA. Many of the
plants chosen in this study are used by the Indian population
not only for food purposes but also form a part of the local
pharmacopoeia for the treatment of diabetes. Our results
indicate that retardation of starch hydrolysis by inhibition of
HPA activity by some of these extracts leads to a reduction
in glucose concentrations (Figure 5). Of the 11 plants and
their 91 extracts tested, 10 exhibited signiﬁcant inhibition
of HPA, suggesting that they contain compounds capable
of HPA inhibition. Of these, 4 are aqueous extracts while 6Evidence-Based Complementary and Alternative Medicine 7
Table 2: Qualitative phytochemical analysis of the extracts exhibiting ≥50% inhibition on PPA and HPA enzyme activity.
Plant species Alkaloids Proteins Tannins Cardiac glycosides Flavonoids Saponins Steroids
B. orellana L. − ++ + − ++
(ME)
C. verum ++ + + − ++
J. S. Presl (IPE)
C. longa L. + − + − ++ +
(IPE)
C. longa L. + − + − + − +
(AE)
F. bengalensis L. ++ + − ++ −
(CWE)
F. bengalensis L. ++−− ++ −
(HWE)
M. koenigii L. + − ++ − ++
Spreng (IPE)
S. cumini L. ++ + − ++ −
Skeels. (CWE)
S. cumini L. ++ + − ++ −
Skeels. (HWE)
T. terrestris L. + −− − ++ −
(AE)
+: Detected; −:N o td e t e c t e d ;C W E :C o l d - w a t e re x t r a c t ;H W E :H o t - w a t e re x t r a c t ;M E :M e t h a n o le x t r a c t ;I P E :I s o p r o p a n o le x t r a c t ;A E :A c e t o n ee x t r a c t .
Table 3: GCMS identiﬁcation of compounds in organic solvent extracts of plants inhibiting HPA enzyme activity.
Plant Name of the compound Molecular formula Molecular weight Area % Retention time (min)
B. orellana L. β-tocopherol C28H48O2 416 38.85 24.29
(ME) Vitamin E C29H50O2 430 50.17 25.96
C. verum Naphthalene,1,2,3,4-
tetrahydro-1,1,6-trimethyl
C13H18 174 32.20 6.29
J. S. Presl (IPE) Eugenol C10H12O2 164 2.57 11.13
4-acetoxycinnamic acid C11H10O4 206 47.02 12.55
C. longa L. Podocarpic acid C17H22O3 274 48.21 13.69
(IPE) Curlone C15H22O 218 19.53 13.95
Cinnamic-acid C9H8O2 148 7.03 14.79
C. longa L. 3-Cyano-7-hydroxy-4-
methylcoumarin
C11H7NO3 201 42.95 13.66
(AE) Curlone C15H22O 218 17.19 13.97
5-amino-2-hydroxybenzoic
acid
C7H7NO3 153 9.574 17.82
M. koenigii L. Cyclohexanone, 2-methyl-
5-(1-methylethenyl)-
C10H16O 152 18.54 14.8
Spreng (IPE) 2,3,5,6-
tetrachlorohydroquinone
C6H2Cl4O2 247 51.85 24.21
Vitamin E C29H50O2 430 10.56 25.94
T. terrestris L. Sorbinose C6H1206 180 10.27 14.27
(AE) Ethyl crotonate C6H10O2 114 71.36 16.96
M E :M e t h a n o le x t r a c t ;I P E :I s o p r o p a n o le x t r a c t ;A E :A c e t o n ee x t r a c t .8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Pancreatic α-amylase inhibition by Indian medicinal plant extracts as a potential antidiabetes mechanism. Double bar marks (\\)
indicate inhibition of amylase activity leading to a reduction of maltose, oligosaccharide and glucose concentration. ME: Methanol extract;
AE: Acetone extract; IPE: Isopropanol extract; CWE: Cold-water extract; HWE: Hot-water extract.
areextractsofless-polarsolvents.Preliminaryphytochemical
analysis to indicate the kind of compounds present in these
extracts suggests the occurrence of proteins/peptides and
polyphenols in cold-and hot-water extracts while tannins,
alkaloids, ﬂavonoids, and saponins are found in non-polar
extracts. Flavonoids and polyphenolics have been reported
to contribute to hypoglycemic activity [30].
B. orellana methanol extract exhibited concentration
independentinhibitionwithanIC50 valueof49μgmL−1.The
major components identiﬁed in this extract were found to be
β-tocopherols and vitamin E which are known to be present
in B. ornella leaves [31].
C. verum inhibited HPA in a concentration-dependent
mannerwithalowIC50 valueof1.0μgmL−1.Themajorcom-
ponents identiﬁed were naphthalene, 1, 2, 3, 4-tetrahydro-
1, 1, 6-trimethyl, eugenol, and 4-acetoxycinnamic acid and
have been previously reported [32, 33].
C. longa is known to contain curcuminoids, glycosides,
terpenoids, and ﬂavonoids [34]. Maximal inhibition of the
enzyme (HPA) was obtained with C. longa isopropanol
extract at a low concentration of 0.16μgmL−1 in a com-
petitive manner and with acetone extract at 7.4μgmL−1 in
a concentration independent manner. The probable com-
poundsinC.longaisopropanolextractwerepodocarpicacid,
curlone, and cinnamic acid while those in acetone extract
were curlone, 3-cyano-7-hydroxy-4-methylcoumarin, and 5-
amino-2-hydroxybenzoic acid.
F. bengalensis bark extract showed HPA inhibitory
activity in the aqueous fraction with an IC50 value of
4.4μgmL−1 in a concentration-dependent manner. The
major phytochemical components in the aqueous extract
were found to be alkaloids, proteins, tannins, ﬂavonoids, and
saponins while cardiac glycosides and steroids were found
to be absent. A dimethoxy derivative of leucocyanidin 3-O-
beta-D-galactosyl cellobioside isolated from the bark of F.
bengalensis Linn. has been shown to decrease blood sugar
levels signiﬁcantly both in normal and moderately diabetic
rats [35].
The compounds identiﬁed in M. koenigii isopropanol
extract were cyclohexanone 2-methyl-5-(1-methylethenyl),Evidence-Based Complementary and Alternative Medicine 9
2, 3, 5, 6 tetrachlorohydroquinone, and Vitamin E which
have been reported in leaves by other investigators [36, 37].
The extract was able to inhibit HPA in a concentration
independent manner with an IC50 value of 127μgmL−1.
Kinetic analysis also indicated that this extract resulted in
the best decrease in both Km and Vmax values to 1.02mg and
0.07μMmin−1 as compared to control, namely, 2.12mg and
0.17μMmin−1.
S. cumini is known to contain proteins, tannins, an
alkaloid jambosine, a glycoside antimellin, and fatty acids
[38]. The extracts exhibiting concentration-dependent HPA
inhibitory activity were cold-and hot-water extracts with an
IC50 value of 42.1 and 4.1μgmL−1,r e s p e c t i v e l y .I ti sm o s t
likely that the bioactive component could probably be a
protein, a glycoside, or a polyphenol.
Furostanol and spirostanol saponins, ﬂavonoids, alka-
loids, steroids, carbohydrates, and amides have been isolated
from T. terrestris [39]. In our study, the acetone extract-
inhibited HPA activity in a concentration independent man-
ner with a high IC50 value of 511μgmL−1. The compounds
identiﬁed in this extract were ethyl crotonate and sorbinose.
These ﬁndings suggest that inhibition of HPA activity,
leading to retardation of starch hydrolysis is one of the
mechanisms through which the plants tested in this study
could be exhibiting their hypoglycemic eﬀect. Modulation
of HPA activity by compounds in these extracts would thus
eventually lead to a lowering of post-prandial blood glucose
levels (Figure 5). Presence of HPA inhibitor blocks the
normal pathway of conversion of dietary starch to maltose,
maltotriose, and oligosaccharides and then to glucose in
the gut which gets absorbed in the blood. Thus, glucose
formation can be blocked in hyperglycemic conditions
with pancreatic α-amylase inhibitors. This HPA inhibition
could occur in a concentration dependent or independent
manner depending upon the bioactive compound. The com-
pounds/bioactive principle from these plants responsible
for the HPA inhibition need to be isolated and charac-
terized. The eﬃcacy of HPA inhibition can be increased
with the combination of these isolated components as
shown by Said et al., where in herbal combination of four
plants is more eﬀective as antidiabetic traditional medicine
[40].
5. Conclusions
This study highlights the HPA inhibitory activity of 10
plant extracts exhibiting promising leads as HPA inhibitory
molecules and lends scientiﬁc support to their use in
traditional Ayurvedic medicine. B. orellana, F. bengalensis,
S.c u m i n i , C. verum, M. koenigii, C. longa,a n dT. terrestris
plants, which are known for their hypoglycemic property,
were found to exhibit strong inhibitory action on HPA,
even better than acarbose. The phytochemicals in the
extracts causing this inhibition were identiﬁed as alkaloids,
proteins, tannins, cardiac glycosides, ﬂavonoids, saponins,
andsteroids.Studiestoisolatethebioactiveprinciple(s)from
these extracts are required. In the recent years, the search
for new molecules as potential α-amylase inhibitors with a
high speciﬁc aﬃnity has intensiﬁed. Thus, modulation of
HPA activity through the therapeutic use of high-aﬃnity
plant derived inhibitors would be of considerable medical
relevance in the treatment of diabetes.
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